Diagnostic approaches based on multimodal imaging of clinical noninvasive imaging (eg. MRI/CT scanner) are highly developed in recent years for accurate selection of the therapeutic regimens in critical diseases. Therefore, it is highly demanded in the development of appropriate all-in-one multimodal contrast agents (MCAs) for the MRI/CT multimodal imaging. Here a novel ideal MCAs (F-AuNC@Fe 3 O 4 ) were engineered by assemble Au nanocages (Au NC) and ultra-small iron oxide nanoparticles (Fe 3 O 4 ) for simultaneous T 1 -T 2 dual MRI and CT contrast imaging. In this system, the Au nanocages offer facile thiol modification and strong X-ray attenuation property for CT imaging. The ultra-small Fe 3 O 4 nanoparticles, as excellent contrast agent, is able to provide great enhanced signal of T 1 -and T 2 -weighted MRI (r 1 = 6.263 mM −1 s −1 , r 2 = 28.117 mM −1 s −1 ) due to their ultra-refined size. After functionalization, the present MCAs nanoparticles exhibited small average size, low aggregation and excellent biocompatible. In vitro and In vivo studies revealed that the MCAs show long-term circulation time, renal clearance properties and outstanding capability of selective accumulation in tumor tissues for simultaneous CT imaging and T 1 -and T 2 -weighted MRI. Taken together, these results show that asprepared MCAs are excellent candidates as MRI/CT multimodal imaging contrast agents.
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The development of personalized therapeutical approaches and the increasing precision of surgical techniques indicate the importance of multimodal imaging to assist physicians in diagnosis and monitoring the response to therapy. In particular, noninvasive imaging (eg. MRI and CT) and minimally invasive in vivo bioimaging techniques are valuable tools in the arsenal of clinical diagnostics [1] [2] [3] . The new emergence of MRI/CT scanner (eg. General Electric CT & MRI scanners) allows doctors to get more precise information of tumor localization and boundary identification by combination of MRI and CT imaging. Accompanied with the development of imaging technology, high-performance, especially those all-in-one multimodal contrast agents (MCAs) are highly demanded for accurate diagnosis and therapy. In the past several years, various of MCAs based on Au and Fe 3 O 4 nanoparticles have been developed for in vivo and pre-clinical MRI/CT imaging with the purpose of increasing the contrast of lesion, because these nanoparticles can offer facile thiol modification, enhanced chemical stability, excellent biocompatibility, superparamagnetic capability, and strong X-ray attenuation property [4] [5] [6] [7] [8] [9] [10] [11] [12] . However, the achievement of these MCAs by using Fe 3 O 4 and Au shell always have low MRI contrast capability, because common Fe 3 O 4 can only provide T 2 weight MRI with dark imaging and Au shell coated on the surface of Fe 3 O 4 also prevent the connection with water molecules in tissue resulting in the reduction of the MRI contrast signal.
To address above problem, here we have exploited a new folic acid functionalized MCAs (F-AuNC@Fe 3 O 4 ), based on Au nanocages (AuNCs) and ultrasmall Fe 3 O 4 nanoparticles, to associate in one signal nanosystem several different properties, such as, tumor targeting, bright T 1 and dark T 2 dual MRI contrast enhancement, and X-ray attenuation (Fig. 1) . Compared with other multimodal imaging systems, our presented MCAs are the first engineered for simultaneous T 1 -T 2 dual MRI and CT contrast. The simultaneous T 1 and T 2 weight contrast imaging could great enhance the sensitivity of MRI to give the comprehensive high spatial resolution of soft tissue information for tumor contour and localization, while the real-time and three-dimensional high spatial Scientific RepoRts | 6:28258 | DOI: 10.1038/srep28258 resolution of hard tissue information for tumor contour and localization could be provided by CT imaging. The use of noninvasive imaging like MRI and CT, possible with our MCAs, can provide the complementary information necessary for accurate evaluation of the tumorigenesis areas, which is one of the major challenges of diagnostic imaging.
Results and Discussion
Synthesis and Characterization of F-AuNC@Fe 3 O 4 . It have been demonstrated that the size control and further surface functionalization are two key factors in the development of high-performance nanoprobes for tumor targeting 13 . Because AuNC@Fe 3 O 4 has no selectivity toward tissues and is unable to discriminate between malignant and nonmalignant tumors, conjugation of specific bimolecular (folic acid) with AuNC@Fe 3 O 4 has been employed to improve their lesion targeting selectivity. The final nanoparticles were purified by gel filtration using Sephacryl HR-300 gel medium.
High-resolution transmission electron microscopy (HRTEM) images of the ultra-small sized Fe 3 O 4 nanoparticles and Au nanocage are shown in Figs S1 and S2 (Supporting Information). The average diameter of the Fe 3 O 4 nanoparticles is around 2.2 nm with high uniformity, which could provide simultaneous T 1 and T 2 weight MRI contrast imaging proved in our previous work 9 . Au nanoparticles exhibit perfect nanocage structure with outer diameters of around 50 nm 14 . After assembled together, the HRTEM and SEM of final F-AuNC@Fe 3 O 4 are shown in Fig. 2a and at the other hand, the nanocages structure also gives their high surface to volume ratio, which also could benefit CT signal enhancement 15, 16 . The Dynamic light scattering (DLS) (Fig. 2e) showed that the hydrodynamic diameter of F-AuNC@Fe 3 O 4 was around 110 nm, which indicated that they have smaller size in aqueous without any aggregation and could process reasonable blood circulation time and good lesion accumulation rate 13 . Inductively coupled plasma mass spectrometry (ICP-MS) study revealed that weight percentages of Au and Fe 3 O 4 encapsulated were 58.2 and 17.2%, respectively.
The UV-vis absorption spectra of the Au nanocage and F-AuNC@Fe 3 O 4 in aqueous suspension are shown in Fig. 2f , and the absorption spectra of ultra-small sized Fe 3 O 4 nanoparticles is provided in Fig. S3 (Supporting Information). Here, Au nanocages and F-AuNC@Fe 3 O 4 exhibits very strong and broad absorption from 600 nm to 800 nm with the maximum absorption at around 750 nm. After deposition of ultra-small sized Fe 3 O 4 nanoparticles onto the surface of Au nanocage, a new broad absorption band appears in the spectrum of F-AuNC@Fe 3 O 4 , which is contributed by the strong absorption of Fe 3 O 4 nanoparticles in visible spectral region 17 .
CT, Relaxometric and Biocompatible Properties. CT X-ray CT imaging owing to the larger X-ray absorption efficiency of Au element. As known, the higher the atomic number and electron density is, the higher the attenuation coefficient is. Therefore, the developed F-AuNC@ Fe 3 O 4 was expected that have the good imaging ability in X-ray CT imaging. The X-ray attenuation (CT) potency of these F-AuNC@Fe 3 O 4 with various concentrations of Au was examined and the pure Au nanoparticles (ca. 50 nm in diameter) were used as a control. It is clearly that the CT signal of F-AuNC@Fe 3 O 4 increase in a concentration dependent manner (Fig. 3b,c) . Interestingly, the F-AuNC@Fe 3 O 4 exhibit higher X-ray attenuation potency than that of bare Au NPs at the same concentration. According to previous reports, smaller Au nanoparticles exhibited more pronounced X-ray attenuating capability than the larger one, which caused by the high surface to volume ratio and mainly contributed to X-ray attenuation 4, 16 . Therefore, the enhanced CT contrast of F-AuNC@ For biomedical applications, it is necessary to guarantee the hemocompatibility and cytocompatibility 7, 18 . Hemolytic assay and cell viability was used to assess the biocompatibility of the F-AuNC@Fe 3 O 4 , the results (Figs S4 and S5, Supporting Information) show synthesized F-AuNC@Fe 3 O 4 have almost negligible damage to the red blood cells (< 5% hemolytic activity) and have little toxicity to human lung cancer cell line A549 and normal human umbilical vein endothelial cells.
In vitro cellular uptake assay. The targeting ability of F-AuNC@Fe 3 O 4 to folate receptor-overexpressed cancer cells was studied using A549 cells as an example. To more directly display the targeting capabilities of the F-AuNC@Fe 3 O 4 , the fluorescence Cy5-PEG-SH was selected to label the nanoparticls. In order to give clear fluorescence imaging and retain the ability of bio-functionalization, firstly, the mixture of COOH-PEG-SH and fluorescence Cy5-PEG-SH with 9:1 ratio was used to functionalize the surface of AuNC@Fe 3 In vivo CT, T 1 and T 2 modal MR Imaging. For in vivo CT imaging, the CT imaging and CT value of the important organ regions were recorded before injection and at different time points post injection (Fig. 5a,b) . Compared with the image of pre-injection, a great contrast enhancement was observed in the mouse body, tail vein and tumor region at 0.5 hour after injection, (Fig. 5a) , demonstrating that the as synthesized F-AuNC@Fe 3 O 4 can do enhance CT imaging in the circulating system. It is noted that the F-AuNC@Fe 3 O 4 have a clear tendency of accumulation in the tumor tissue, the time-dependent distribution of the F-AuNC@Fe 3 O 4 in the mouse was also tracked by CT signal value after intravenous injection. At timed intervals, the evident enhancement of the signals in different organs could be seen in Fig. 5b , the kidney and tumor imaging were greatly enhanced from 0.5 h to 6 h, and HU value of them rose from 95 to 464 and 213 to 730, respectively, while the signal value in other organs shows little fluctuation. A more careful look at the 3D-renderings of CT images, after post injection 6 h, the CT For tumor targeting T 1 and T 2 modal MR imaging, the F-AuNC@Fe 3 O 4 with higher r 1 and r 2 relaxivity are expected to enhance the T 1 and T 2 modal MRI and to ease the toxicity with a decreased dose. T 1 and T 2 modal MRI of tumor-bearing mice were also recorded at various time intervals: before injection, 0.5, 1 and 6 hours after injection, as shown in Fig. 6a . Compared with pre-injection, we could observe a great contrast enhancement (brighten on the T 1 -weighted and darken on the T 2 weighted MR images) in the mouse body after post injection, demonstrating that as synthesized F-AuNC@Fe 3 O 4 can simultaneously enhance T 1 and T 2 relaxation in the circulating system. The enhanced signal of blood vessel can be maintained for more than 6 h, which is much longer than that of Gd complex small molecules with a high excretion rate (about several minutes in small animals) 9, 19 . These results show that F-AuNC@Fe 3 O 4 can also be used for long-term blood pool T 1 and T 2 modal MRI contrast agent, which is very important in clinical MR imaging 20, 21 . The long-term effect is also critical to obtain high-resolution and steady state images. Similar with the CT imaging, after 6 h, the T 1 and T 2 contrast intensity in the body of mouse obviously decrease over time, while the contrast intensity in the region of tumor increased over time, which confirm the F-AuNC@Fe 3 O 4 have a tendency to be enriched in the tumor tissue.
In general, once injected intravenously, the contrast agents are easily accumulated in liver and spleen tissues 22 . Therefore, to provide further support of tumor targeting ability as well as information on the biodistribution of the F-AuNC@Fe 3 O 4 , both tumor and important organs such as heart, liver, spleen, kidney and tumor were harvested after the in vivo experiments, and the MRI with T 1 and T 2 modal was shown in Fig. 6b , respectively. At first, the much higher T 1 and T 2 signals in the tumor tissue compared to those from other organs further confirm the specific targeting of the FMNPs to the tumor. And then, the imaging signal of organs might be difference between MRI imaging and CT imaging, which is why we integrate MR imaging with CT imaging for achieving their complementary imaging features.
Histological study. An essential feature of MCAs is their biocompatibility, hence primary organs of tumor bearing mice post the administration of F-AuNC@Fe 3 O 4 were tested via the pathological assay (H&E staining). In Fig. 7 , the accumulation of F-AuNC@Fe 3 O 4 was obviously observed in kidney, bladder and tumor (original magnification × 100), but it was little even absence in liver and heart at 6 h post the injection, which is in consistent with our in vivo imaging findings. In addition, no observable morphological changes were seen in these organs, which ruled out the presence of acute injury induced by the injection of F-AuNC@Fe 3 O 4 .
In summary, water-dispersible F-AuNC@Fe 3 O 4 nanoparticles-based multimodal contrast agent has been developed for synergistically multimodal imaging of tumor. To the best of our knowledge, this is the first time that ultra-small sized Fe 3 O 4 and Au nanocages were assembled together to provide simultaneous CT imaging and T 1 and T 2 -modal MRI of tumor bearing mice. As a result, due to the small sizes and surface modification, the as-prepared F-AuNC@Fe 3 O 4 preferentially accumulate in the tumor, and can be rapidly eliminated from the body via the renal system. The experimental results suggest the potential of F-AuNC@Fe 3 O 4 as a safe and efficient contrast agent for biomedical applications such as multi-modality imaging and molecular diagnostics of diseases in vitro and in vivo, as well as theranostic applications. 
Methods
All experimental protocol including any relevant details were approved by the Regional Ethics Committee, Liaoning Medical University, Liaoning Province, China.
Materials and Instrumentations.
All of the chemicals and solvents were purchased from Sigma-Aldrich unless indicated otherwise. Transmission electron microscope (TEM) and energy dispersive X-ray (EDX) analyses were recorded using a FEI TECNAI G20 high-resolution transmission electron microscope operating at 200 kV. The samples were prepared by depositing a drop of a diluted colloidal solution on a carbon grid and allowing the liquid to dry in air at room temperature. Scanning electron microscope (SEM) data was collected by Hitachi Limited S4800. Dynamic light scattering (DLS) measurement was performed on a Malvern Zetasizer NANO ZS. UV-vis spectroscopy was carried out with SpectraMax ® M5 Microplate Reader using 96-well plate .
The relaxation measurements were performed on a Bruker minispec mq60 NMR analyzer at 40 °C using a magnetic field of 1.41 T. Samples were diluted in MilliQ water to different Fe and Au concentrations in the approximate range, and the absolute concentrations were determined afterwards by ICP-MS.
Synthesis of Gold Nanocages (AuNCs).
Herein, Au cages with hollow structures using Ag nanocubes as sacrificial templates have been prepared according to previous methods 12 . For all of the experiments, we used Au nanocages of mean 50 nm size together with a pore size of 2-3 nm. Briefly, 500 μ L of the Ag nanocubes (3 nM) was added to 5 mL of deionized water containing poly (vinyl pyrrolidone) (PVP, 1 mg mL −1 ) hosted in a 50 mL flask Figure 5 . In vivo CT images of nude mice bearing tumor after intravenous injection of Au NPs at different timed intervals (pre-injection, 0.5 h, 1 h and 6 h post-injection), respectively (a) The HU average intensity of some organs (Heart, Liver, Spleen, Kidney, Tumor) after intravenous injection of Au NPs at different timed intervals.
Scientific RepoRts | 6:28258 | DOI: 10.1038/srep28258
under magnetic stirring and then heated to boil for 10 min. Then around 4 mL of aqueous solution of HAuCl 4 (0.1 mM) was added to the flask at a rate of 0.75 mL min −1 until the solution had an optical extinction peak at 755 nm as confirmed by UV spectroscopy. The solution was refluxed for another 10 min until the color of the reaction was stable. Once cooled to room temperature, the sample was centrifuged and washed with saturated NaCl solution to remove AgCl and with water several times to remove PVP and NaCl. For the further experiment, The PVP was replaced on nanocages with 2-aminoethanethiol to obtain AuNC-NH 2 .
Synthesis of AuNC@Fe 3 O 4 . In a typical experiment for the synthesis of 2.2 nm sized ultra-small Fe 3 O 4 particles was prepared according to our previous experiment. First, the polymer poly(acrylic acid) (PAA, 5.56 mmol) was dissolved in Milli-Q water (50 mL) in a 100 mL three-necked flask bubbled with nitrogen air for 40 min to remove oxygen. Then the solution was heated up to 80 °C. Meanwhile, Ferric slat (0.54 mmol) and Ferrous salt (0.279 mmol) as iron precursors was quickly injected into the hot polymer solution under vigorous stirring in a nitrogen atmosphere, followed by drip addition of concentrated ammonia solution (15 mL, 28%) to adjust the pH value to 9-10. After refluxing for one hour, we can get the carboxyl group functionalized ultrasmall Fe 3 O 4 particles.
The resultant carboxyl unit on the surface of Fe 3 O 4 nanoparticels was activated by N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide (EDC) and N-Hydroxysuccinimide (NHS), and subsequently treated with AuNC-NH 2 to obtain AuNC@Fe 3 O 4 . 10 mg of excessive ultrasmall Fe 3 O 4 nanoparticles was reacted with 10 mg NHS and 20 mg EDC in 5 mL of water, stirring at room temperature for 30 min before adding to the 5 mg of AuNC-NH 2 suspension. Then the mixture was stirred at room temperature for another 24 h, followed by centrifugation and washing with ethanol and water, and then dispersed in 5 mL of ultra-purified water. The bio-conjugation was performed by EDC-catalyzed peptide bond formation between the carboxyl group on the particle surface and amino group on folic acid. First, 10 mL of freshly prepared EDC solution (10 mg mL −1 in weak acidic MES buffer solution) was mixed with 1 mL HNPs solution with stirring for one hour. Then, 50 mL folic acid solution (containing 0.4% NaOH) was added to the solution and mixed well on a vortex, and then the above mixture was left on a rotary shaker overnight at room temperature. After that, the Triton-X 100 (0.25% (w/v), 20 mL) and BSA (2% (w/v), 20 mL) were added. The mixture was then left on the rotary shaker for one hour. Finally, the resulting folic acid functionalized AuNC@Fe 3 O 4 (F-AuNC@Fe 3 O 4 ) were separated from free biomolecules by gel filtration using Sephacryl HR-300 gel medium.
Bio-functionalized of AuNC@Fe
In vitro cytotoxicity study. Human lung adenocarcinoma A549 cells and human umbilical vein endothelial cells (HUVEC) were cultured in 25 cm 2 flasks in Dulbecco's Modified Eagle's Medium DMEM (Gibco) containing 10% (v/v) fetal bovine serum (Gibco) at 37 °C in an atmosphere of 5% (v/v) CO 2 in air. The media were changed every two days, and the cells were passaged by trypsinization before confluence. Before experiment, the cells were pre-cultured until confluence was reached. For studying the cytotoxicity, both A549 and HUVEC cells were seeded in a 96-well plate at a density 10 4 cells/well for 24 h at 37 °C in 5% CO 2 . Then, the cells were treated with F-AuNC@Fe 3 O 4 at different concentrations of 100, 200, 300, 400, 500 and even 1000 μ g mL −1 . After incubation for 24 h, cell viabilities were tested by standard MTT (3-(4,5)-dimethylthiahiazo-2-yl)-2,5diphenyltetrazolium bromide) assay. Cells incubated in the absence of nanoparticles were used as a control. All experiments were performed in triplicate.
Hemolysis assay. In order to detect whether F-AuNC@Fe 3 O 4 will cause damage to red blood cells (RBCs) after being injected into the blood vessels, a hemolysis assay experiment was carried out. The red blood cells were obtained by removing serum from the blood by centrifugation and suction. The 0.5 mL cells suspension was then mixed with: (a) 1 mL of PBS as a negative control; (b) 1 mL deionized water as a positive control; (c) 1 mL nanoparticle PBS solution with different concentrations of 100, 200, 400, 800 and 1000 μ g mL −1 . The mixtures were then vortexed for 2 h at room temperature. The samples were centrifuged and the absorbance spectrum of the supernatants was measured by UV-Vis characterization. In vivo CT, T 1 and T 2 -weight MRI tri-modal imaging. Male BALB/c nude mice (4-6 weeks old) were purchased from the Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing. The Lung cancer A549 tumor-bearing models were generated by subcutaneous injection of 5 × 10 6 cells in 50 μ L of phosphate buffer solution (PBS) onto the left upper armpit of each mice. All the animal experiments were conducted in accordance with the guidelines of the Regional Ethics Committee, Liaoning Medical University, Liaoning Province, China. Firstly, the mice were anesthetized using 10% chloral hydrate (50 mL). Subsequently, 10 mg of F-AuNC@Fe 3 O 4 , dispersion solution was injected through the tail vein into the mouse. In vivo multi-imaging was performed at appropriate time points after tail vein injection.
In vitro
CT imaging was acquired using Mediso nanoScan SPECT/CT produced by Mediso Ltd. Imaging parameters were as follows: slice thickness, medium; tube energy, 50 kVp, 670 μ A; CTDIvol, 7279.9 cGy; semicircular parameters, full scan; Number of projections, 480; In-plane voxel size, medium. All animals were scanned in the cranial to caudal direction from the lower chest to the pelvis. CT data were analyzed using the Hounsfield units (HU) for regions.
In vivo MR imaging experiments were performed on a 3.0 T small animal MRI instrument (US Varian 3.0 T), and the pulse sequence used was a T 1 After injected with 10 mg F-AuNC@Fe 3 O 4 , the tumor bearing mice were sacrificed at 6 h post-administration and the tissues including heart, kidney, liver, spleen and tumor were harvested for isolated organ imaging.
Histological study. Potential acute cytotoxicity and bio-distribution in major organs (heart, liver, lung, kidney, bladder and tumor) of tumor bearing mice post intravenous injection were assessed by dissection. Typical organs were harvested from the rats and immobilized in 4% paraformaldehyde at 4 °C for 48 h, and then embedded into paraffin. Sections from the organs were stained with hematoxylin and eosin (H&E) and observed under a light microscope at 100× magnification by an experienced physician, and representative images were provided.
